University Of Washington

Approximately 40% of physicians experience some form of burnout, according to national surveys.

In his editorial in this issue, Derek Raghavan, MD, PhD, expresses exasperation with the field of cancer epidemiology — noting, in particular, its large number of seemingly duplicative studies and the “litany of papers reporting weak associations.”

In a study of 68 children with juvenile idiopathic arthritis, about half had obstructive sleep apnea, according to recently published results.

Children with Crohn’s disease and ulcerative colitis achieved clinical remission after specific carbohydrate diet therapy, according to the results of a small prospective study.

SAN DIEGO — The addition of brentuximab vedotin to salvage chemotherapy before autologous stem cell transplantation may safely and effectively treat patients with relapsed or refractory classical Hodgkin lymphoma, Ryan D. Cassaday, MD, told HemOnc Today at the ASH Annual Meeting and Exposition.

WASHINGTON — At the American College of Rheumatology Annual Meeting, Philip J. Mease, MD, rheumatologist at Swedish Medical Center and clinical professor at the University of Washington, discussed tofacitinib — an oral Janus kinase inhibitor — and its effectiveness against psoriatic arthritis as demonstrated in two studies.

Mechanical ventilation rates increased by 100% in patients with advanced dementia, but these rates were not linked with significant improvement in survival, according to findings published in JAMA Internal Medicine.

The prevalence of diabetic kidney disease in the United States remained unchanged from 1988 to 2014, but the frequency of albuminuria decreased and the frequency of reduced estimated glomerular filtration rate increased, according to findings published in JAMA.

Adults with mild to moderate obesity randomly assigned to Roux-en-Y gastric bypass saw a significantly greater diabetes remission rate vs. patients assigned to an intensive lifestyle and medical intervention, according to an analysis of the CROSSROADS trial.

The treatment and management of patients with HF has taken a dramatic leap in the past year. Although HF remains one of the most difficult heart diseases to treat, the introduction of new drugs and new technologies has improved the outlook for many patients with HF.